Clinical Trials
Study Title:
EF 32 (TRIDENT): A Pivotal Randomized, Open Label Study of Optune® (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
|
For more information about the trial above please contact the study team:
|